Key result
Direct acting antiviral therapy in chronic HCV patients was associated with decreased risk of MACE (HR 0.73; 95% CI 0.59-0.92; P=0.007), heart failure, VTE, and all-cause mortality at 3 years.
Why the study?
Chronic HCV infection is associated with increased cardiovascular risks, but the impact of direct acting antiviral therapy on HCV-associated cardiovascular events required investigation.
Does direct acting antiviral therapy reduce cardiovascular events and mortality in patients with chronic hepatitis C virus infection?
Cohort (n=2,397)
Yes
Does direct acting antiviral therapy reduce cardiovascular events and mortality in patients with chronic hepatitis C virus infection?
Hazard Ratio: 0.73 (95% CI 0.59–0.92)
p-value: p=0.007
Direct acting antiviral therapy in patients with chronic HCV infection is associated with a significant reduction in major adverse cardiovascular events, venous thromboembolism, and all-cause mortality.
DAA therapy was associated with fewer CV events in chronic HCV; hypothesis-generating and requires prospective confirmation before practice change.
BACKGROUND: Chronic hepatitis C virus (HCV) infection is associated with increased cardiovascular risks. We aimed to investigate the impact of direct acting antiviral (DAA) on HCV-associated cardiovascular events. METHODS: In this retrospective cohort study, patients with the diagnosis of chronic HCV were retrieved from multi-institutional electronic medical records, where diagnosis of HCV was based on serum HCV antibody and HCV-RNA test. The patients eligible for analysis were then separated into patients with DAA treatment and patient without DAA treatment. Primary outcomes included acute coronary syndrome, heart failure (HF), venous thromboembolism (VTE), stroke, cardiovascular death, major adverse cardiovascular event (MACE), and all-cause mortality. Outcomes developed during follow-up were compared between DAA treatment and non-DAA treatment groups. RESULTS: There were 41 565 patients with chronic HCV infection identified. After exclusion criteria applied, 1984 patients in the DAA treatment group and 413 patients in the non-DAA treatment group were compared for outcomes using inverse probability of treatment weighting. Compared to patients in non-DAA treatment group, patients in DAA treatment group were associated with significantly decreased HF (hazard ratio [HR]: 0.65, 95% confidence interval [CI]: 0.44-0.97, P = 0.035), VTE (HR: 0.19, 95% CI: 0.07-0.49, P = 0.001), MACE (HR: 0.73, 95% CI 0.59-0.92, P = 0.007), and all-cause mortality (HR: 0.50, 95% CI: 0.38-0.67, P < 0.001) at 3-year follow-up. CONCLUSIONS: Chronic HCV patients treated with DAA experienced lower rates of cardiovascular events and all-cause mortality than those without treatment. The reduction of VTE was the most significant impact of DAA treatment among the cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2023) conducted a cohort in Chronic hepatitis C virus (HCV) infection (n=2,397). Direct acting antiviral (DAA) therapy vs. No DAA treatment was evaluated on Major adverse cardiovascular event (MACE) (HR 0.73, 95% CI 0.59-0.92, p=0.007). Direct acting antiviral therapy in chronic HCV patients was associated with decreased risk of MACE (HR 0.73; 95% CI 0.59-0.92; P=0.007), heart failure, VTE, and all-cause mortality at 3 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: